Wire · opportunities
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA approved Infilbray (venglustat), the first drug to treat neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients, which can cross the blood-brain barrier to reduce harmful substance accumulation in the brain and body.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You just gained access to a rare neurological treatment market with FDA backing for Type 3 Gaucher disease. Start exploring patient groups and specialists focused on rare genetic disorders to pitch your solutions now.
◆ Coverage
2 sources · 18 Nov 2026
◆ Related on Wire
◆ Topics